Table 3.

Univariate and multivariate analyses of overall survival.

Characteristic	Univariate analysisHazard ratio (95% CI)	p	Multivariate analysisHazard ratio (95% CI)	p
Age (years)	1.153 (0.811–1.640)	0.427	–	–
T stage#	2.415 (1.547–3.771)	<0.001*	1.633 (1.027–2.596)	0.038*
N stage#	5.572 (3.823–8.121)	<0.001*	4.719 (3.195–6.971)	<0.001*
Histopathological Type	2.674 (1.306–5.473)	0.007*	2.668 (1.302–5.468)	0.007*
ER status	0.572 (0.399–0.822)	0.002*	0.902 (0.521–1.563)	0.713
PR status	0.568 (0.399–0.808)	0.002*	0.695 (0.483–0.998)	0.049*
HER-2 status	1.691 (1.181–2.421)	0.004*	1.231 (0.845–1.793)	0.279
Ki-67	2.197 (1.526–3.162)	<0.001*	1.713 (1.175–2.497)	0.005*
NLR group	1.440 (1.0122.051)	0.043*	1.598 (0.574–2.365)	0.064
PLR group	1.488 (0.981–2.232)	0.062	–	–
SII group	1.356 (0.903–2.037)	0.142	–	–
PIV group	1.737 (1.096–2.755)	0.016*	1.720 (1.083–2.730)	0.021*

A Cox proportional hazards model was used to conduct multivariate analyses. All variables were transformed into categorical variables. HRs of variables were calculated as follows: Age (>48 vs. ≤48 years); T stage (T1 vs. T234); N stage (N012 vs. N3); histological Type (invasive ductal carcinoma vs. others); ER (negative vs. positive); PR (negative vs. positive); HER-2 (negative vs. positive); Ki-67 (≤14% vs. >14%); NLR group (≤1.99 vs. >1.99); PLR group (≤160.25 vs. >160.25); SII group (≤642.23 vs. >642.23); PIV group (≤310.20 vs. >310.20).

HR, hazard ratio; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; PIV, pan-immune-inflammation value.

^#According to the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system.

^*p < 0.05.